市場調查報告書
商品編碼
1215482
血管炎治療全球市場規模調查和預測:按藥物類別、疾病類型、分銷渠道和地區分析,2022-2029 年Global Vasculitis Treatment Market Size study & Forecast, by Drug Class, by Disease Type, by Distribution Channel and Regional Analysis, 2022-2029 |
2021 年全球血管炎治療市場價值約為 2.501 億美元,預計在 2022-2029 年預測期內將以超過 3.4% 的健康增長率增長。
血管炎治療是一種影響血管的罕見炎症性疾病。 這種炎症會使血管壁變厚,縮短通過它們的通道的寬度,並限制血液流動。 此外,血流受限會導致器官衰竭和組織損傷。 血管炎有多種類型,包括鉅細胞動脈炎(GCA)、大動脈炎(TAK)、主動脈炎、川崎病(KD)和結節性多動脈炎(PAN)。 血管炎的常見症狀和體徵包括發燒、頭痛、疲勞、體重減輕和全身酸痛。 血管炎患病率上升、慢性病患病率上升以及主要參與者的戰略舉措是加速市場增長的關鍵因素。
血管炎患病率的增加促進了全球血管炎治療市場的增長。 例如,根據 Vasculitis UK 的數據,截至 2020 年,血管炎每年影響 2000-3000 名英國居民。 此外,根據美國心臟協會雜誌——截至 2021 年 1 月,瑞典和挪威每年報告的 50 歲及以上人群中每 100,000 人中就有 20 多例 GCA 新病例。 此外,在美國,女性患 GCA 的終生風險估計為 1%,男性為 0.5%。 此外,活性藥物成分 (API) 行業的快速增長和新興市場醫療保健基礎設施的改善將為預測期內的市場提供良好的增長前景。 然而,與皮質類固醇相關的副作用和不利的報銷情況將阻礙整個 2022-2029 年預測期內的市場增長。
全球血管炎治療市場研究中考慮的主要區域是亞太地區、北美、歐洲、拉丁美洲和世界其他地區。 由於主要市場參與者的存在以及該地區血管炎發病率的增加,北美在收入方面佔據了市場主導地位。 另一方面,由於老年人口增加和製藥製造業擴張等因素,預計亞太地區在預測期內將以最高複合年增長率增長。
這項研究的目的是揭示近年來各個細分市場和國家/地區的市場規模,並預測未來幾年的市場規模。 該報告旨在捕捉被調查國家工業的定性和定量方面的情況。
它還提供了關鍵方面的詳細信息,例如決定市場未來增長的驅動因素和挑戰。 此外,它還包含供利益相關者投資的微觀市場潛在機會,以及對主要參與者的競爭格局和產品供應的深入分析。
按藥物類別
生物製品
皮質類固醇和免疫抑製劑
按疾病類型
中小血管炎
大血管炎
按銷售渠道
醫院藥房
藥店/零售商
在線藥店
Global Vasculitis Treatment Market is valued at approximately USD 250.1 million in 2021 and is anticipated to grow with a healthy growth rate of more than 3.4% over the forecast period 2022-2029. Vasculitis Treatment is a rare inflammatory disease which affects blood vessels. The inflammation causes the walls of the blood vessels to thicken, which shortens the width of the passageway through the vessel and restricts blood flow. Moreover, restricted blood flow can result in organ failure and tissue damage. There are many types of vasculitis, such as Giant cell arteritis (GCA), Takayasu's arteritis (TAK), Aortitis, Kawasaki disease (KD), and Polyarteritis nodosa (PAN) among others. The general symptoms and signs of Vasculitis include Fever, Headache, Fatigue, Weight loss, General aches, pains, etc. The increasing vasculitis prevalence and growing incidences of chronic diseases as well as strategic initiatives from leading market players are key factors accelerating the market growth.
The increasing incidences of vasculitis prevalence are contributing towards the growth of the Global Vasculitis Treatment Market. For instance - according to Vasculitis UK - as of 2020, vasculitis affects 2000 to 3000 UK residents every year. Moreover, as per American Heart Association Journal - as of January 2021, in Sweden and Norway more than 20 new cases of GCA per 100 000 individuals aged 50 years and older are reported every year. Additionally, the lifetime risk of developing GCA is estimated at 1% for women and 0.5% for men in the United States. Also, the rapid growth of active pharmaceutical ingredient (API) industry and rising healthcare infrastructure in developing regions would create a lucrative growth prospectus for the market over the forecast period. However, side effects associated with corticosteroids and unfavorable reimbursement scenarios stifle market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Vasculitis Treatment Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the presence of leading market players and increasing incidences of vasculitis in the region. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising geriatric populations, and increasing expansion of pharmaceuticals manufacturing sector in the region.
Major market players included in this report are:
Amneal Pharmaceuticals Inc.
AstraZeneca plc
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Pfizer Inc.
InflaRx N.V
Novartis AG
ChemoCentryx Inc.
AbbVie Inc.
Teva Pharmaceutical Industries Ltd.
Recent Developments in the Market:
Global Vasculitis Treatment Market Report Scope:
Historical Data: 2019-2020-2021
Base Year for Estimation: 2021
Forecast period: 2022-2029
Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered: Drug Class, Disease Type, Distribution Channel, Region
Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Class
Biologics
Corticosteroids and immunosuppressants
By Disease Type
Small and medium vessel vasculitis
Large vessel vasculitis
By Distribution Channel
Hospital pharmacies
Drug stores and retail pharmacies
Online Pharmacies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
List of figures
List of tables and figures and dummy in nature, final lists may vary in the final deliverable